Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903020 | 0.84 | LMNA (0.62) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL27310027 | 0.80 | KMT2A (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4497810 | 0.79 | NPBWR1 (0.65) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL8344521 | 0.78 | NPBWR1 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL2308775 | 0.78 | NPBWR1 (0.79) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4814783 | 0.78 | RAB9A (0.60) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL5566197 | 0.77 | NPC1 (0.78) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL28761269 | 0.77 | RAB9A (0.80) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL30343723 | 0.77 | NPC1 (0.80) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL14447534 | 0.77 | NPC1 (0.80) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009065028-A2 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | BRCA1, BRAP, BCCIP | SMN1; SMN2 1456/4885NPC1 626/4885RAB9A 2880/4885 |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | BRCA1, BRAP, BCCIP | SMN1; SMN2 1492/4885NPC1 614/4885RAB9A 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.